Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.58 |
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6672850 | 1.00 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL3460656 | 1.00 | OTC (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL13043221 | 0.94 | OTC (0.65) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL21611913 | 0.93 | OTC (0.53) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL1768369 | 0.86 | OTC (0.50) | OTCGSRNOD1CYP1A2 | |
| SCHEMBL1768374 | 0.86 | OTC (0.50) | OTCGSRNOD1CYP1A2 | |
| SCHEMBL27841191 | 0.86 | OTC (0.55) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL12238274 | 0.86 | OTC (0.55) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL18924743 | 0.86 | GSR (0.58) | OTCGSRARG2ARG1NOD1 | |
| SCHEMBL5974000 | 0.85 | OTC (0.58) | OTCGSRARG2ARG1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| CN-113301920-B | Complexes comprising a ligand, a spacer, a peptide linker and a biomolecule | 安斯泰来制药株式会社 | 2025-01-14 | — | — | CN | disclosed |
| CN-119100961-A | Preparation method of alkynylamide-mediated thiourea compound and application of alkynylamide-mediated thiourea compound in polypeptide cyclization | 广州医科大学 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024246269-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2024-12-05 | — | — | WO | disclosed |
| EP-4471048-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2024-12-04 | — | — | EP | disclosed |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| US-20240366775-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING ANTIBODY-PEPTIDE CONJUGATE | PEPTIDREAM INC. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-4393959-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING ANTIBODY-PEPTIDE CONJUGATE | PeptiDream Inc. (JP) | 2024-07-03 | — | — | EP | disclosed |
| EP-4389893-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | Takeda Pharmaceutical Company Limited (JP) | 2024-06-26 | — | — | EP | disclosed |
| CN-118201966-A | Human transferrin receptor binding antibody-peptide conjugates | 肽梦想株式会社 | 2024-06-14 | — | — | CN | disclosed |
| WO-2003020901-A2 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020900-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020953-A2 | COMPOSITIONS AND METHODS RELATING TO COLON SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020102610-A1 | Automated identification of peptides | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-08-01 | — | — | US | disclosed |
| US-20020055186-A1 | Detection of peptides | OXFORD GLYCOSCIENCES (UK) LTD. | 2002-05-09 | — | — | US | disclosed |
| WO-2002025287-A2 | DETECTION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002021139-A2 | AUTOMATED IDENTIFICATION OF PEPTIDES | OXFORD GLYCOSCIENCES (UK) LTD. (GB) | 2002-03-14 | — | — | WO | disclosed |
| WO-1994018230-A1 | INHIBITION OF HIV REPLICATION BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORPORATION (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0077796-A1 | NEW MEDICINE COMPRISED OF AN APROTININE-PLASMINE COMPLEX AND METHOD FOR THE PREPARATION OF SUCH NEW COMPLEX | CHOAY S.A. (FR) | 1983-05-04 | — | — | EP | disclosed |
| WO-1982003772-A1 | NEW MEDICINE COMPRISED BY AN APROTININE-PLASMINE COMPLEX AND METHOD FOR THE PREPARATION OF SUCH NEW COMPLEX | VAIREL EDMOND | 1982-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | MUSK, TFRC, SLC7A1 | OTC 2216/4885GSR 2231/4885ARG2 804/4885 |
| US-20240366775-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING ANTIBODY-PEPTIDE CONJUGATE | TFRC, MET, SLC7A1 | OTC 2184/4885GSR 3980/4885ARG2 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.